Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how data help shape first-line treatment decisions in EGFR-mutated non–small cell lung cancer.
Back
Evolving Standards in EGFR-Mutated Non–Small Cell Lung Cancer
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss evolving treatment considerations in EGFR-mutated non–small cell lung cancer.
Evolving Standards in EGFR-Mutated Non–Small Cell Lung Cancer
Episodes
All
All
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss second-line treatment approaches and sequencing considerations in EGFR-mutated non–small cell lung cancer.
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss factors that drive treatment and sequencing planning in EGFR-mutated non–small cell lung cancer.
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how the FDA approval of a subcutaneous formulation of amivantamab will affect clinical practice
Christine Lovly, MD, PhD, and Matthew Lee, MD, detail implementation and safety considerations for subcutaneous amivantamab in EGFR-mutated NSCLC.
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss ongoing research to watch in EGFR-mutated non–small cell lung cancer
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
4
Dr Le on Choosing Between Zongertinib and Sevabertinib in HER2 TKD–Mutant NSCLC
5